<DOC>
	<DOCNO>NCT01752634</DOCNO>
	<brief_summary>This study provide 24 - 52 week efficacy , safety tolerability data support registration secukinumab ( AIN457 ) prefilled syringe ( PFS ) subcutaneous self administration subject active PsA despite current previous NSAID , DMARD and/or anti-TNFα therapy . An additional 4 year long-term efficacy safety data collect post Week 52 period study .</brief_summary>
	<brief_title>Efficacy 24 Weeks With Long Term Safety , Tolerability Efficacy 5 Years Secukinumab Patients Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients eligible inclusion study fulfill follow criterion : Diagnosis PsA classify CASPAR criterion symptoms least 6 month moderate severe PsA must Baseline ≥3 tender joint 78 ≥3 swell 76 ( dactylitis digit count one joint ) Rheumatoid factor antiCCP antibody negative screen Diagnosis active plaque psoriasis nail change consistent psoriasis document history plaque psoriasis Subjects PsA take NSAIDs least 4 week prior randomization inadequate control symptoms least one dose stop due intolerance NSAIDs Subjects take corticosteroid must stable dose ≤10 mg/day prednisone equivalent least 2 week randomization remain stable dose Week 24 Subjects take MTX ( ≤ 25 mg/week ) allow continue medication dose stable least 4 week randomization remain stable dose Week 52 . Patients fulfil follow criterion eligible inclusion study : Chest Xray chest MRI evidence ongoing infectious malignant process , obtain within 3 month prior screen evaluate qualified physician Subjects take high potency opioid analgesic ( e.g . methadone , hydromorphone , morphine ) Previous exposure secukinumab biologic drug directly target IL17 IL17 receptor Ongoing use prohibit psoriasis treatment / medication ( e.g. , topical corticosteroid , UV therapy ) randomization . The following wash period need observe : Oral topical retinoids 4 week Photochemotherapy ( e.g . PUVA ) 4 week Phototherapy ( UVA UVB ) 2 week Topical skin treatment ( except face , scalp genital area screening , corticosteroid mild moderate potency ) 2 week Subjects ever receive biologic immunomodulating agent except target TNFα , investigational approve Previous treatment celldepleting therapy include limited antiCD20 , investigational agent ( e.g. , CAMPATH , antiCD4 , antiCD5 , antiCD3 , antiCD19 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Psoriatic arthritis , PsA , ACR , CASPAR , PASDAS</keyword>
</DOC>